HIVE Digital Technologies Ltd - Common Shares (HIVE)
4.3800
-0.1600 (-3.52%)
NASDAQ· Last Trade: Jun 3rd, 4:29 PM EDT
Detailed Quote
Previous Close
4.540
Open
4.480
Bid
4.360
Ask
4.380
Day's Range
4.310 - 4.945
52 Week Range
1.600 - 7.840
Volume
37,078,234
Market Cap
-
PE Ratio (TTM)
-6.257
EPS (TTM)
-0.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
33,618,395
Chart
About HIVE Digital Technologies Ltd - Common Shares (HIVE)
Hive Digital Technologies Ltd is a technology company that specializes in providing innovative solutions in the fields of digital assets and blockchain. The company focuses on the production and management of cryptocurrency mining operations, leveraging advanced computing technology to facilitate the mining of various cryptocurrencies. In addition to mining, Hive is involved in the development of blockchain-enabled applications and platforms, aiming to enhance the accessibility and adoption of digital currencies. The company's mission is to create sustainable and efficient technology solutions that contribute to the growing ecosystem of digital assets, positioning itself as a key player in the evolving landscape of the cryptocurrency market. Read More
HIVE Digital Technologies (NASDAQ:HIVE) reported sharp year-over-year revenue growth for its fiscal 2026 and used its earnings call to outline an expanded strategy centered on high-performance computing, artificial intelligence infrastructure and continued Bitcoin mining cash flow.
President and Ch
The June 2nd earnings call will give investors more detail on HIVE’s mining profitability, power capacity, and whether its AI/HPC plans are moving from land and power access toward funded capacity and customer commitments.
Oncotelic Therapeutics (OTCQB: OTLC) is advancing its Sapu003 program and Deciparticle platform as part of a strategy focused on improving the delivery, bioavailability and therapeutic consistency of oncology treatments. As biotechnology companies increasingly explore ways to enhance the performance of existing therapies rather than developing entirely new compounds, Oncotelic is leveraging nanotechnology-enabled drug-delivery systems and pharmacokinetic optimization to potentially improve therapeutic outcomes while reducing development risk. The company’s approach aligns with broader industry trends favoring advanced delivery technologies that may offer faster development timelines and expanded commercial opportunities.
BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate. Oncotelic is one of several companies, including Northwest Biotherapeutics Inc. (OTCQB: NWBO), Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (NASDAQ: HIVE) and Iovance Biotherapeutics Inc. (NASDAQ: IOVA), that are building scalable platforms — whether cancer immunotherapy, genomic medicine, AI/data infrastructure or cell therapy — rather than…
AUSTIN, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate. Oncotelic is one of several companies, including Northwest Biotherapeutics Inc. (OTCQB: NWBO), Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (NASDAQ: HIVE) and Iovance Biotherapeutics Inc. (NASDAQ: IOVA), that are building scalable platforms — whether cancer immunotherapy, genomic medicine, AI/data infrastructure or cell therapy — rather than single-product biotechnology stories alone.
IREN is leveraging its massive grid-connected power assets in Texas to secure high-margin artificial intelligence contracts and transform its valuation.
A number of actively traded small-cap and growth stocks are drawing increased investor attention as momentum continues building across sectors tied to AI infrastructure, biotechnology, GLP-1 healthcare, vaccines, high-performance computing, and digital infrastructure. Names currently trading actively include ENDRA Life Sciences Inc. (NASDAQ: NDRA), Sunshine Biopharma Inc. (NASDAQ: SBFM), GeoVax Labs Inc. (NASDAQ: GOVX), HIVE Digital Technologies Ltd. (NASDAQ: HIVE), and Sphere 3D Corp. (NASDAQ: ANY).
ENDRA Life Sciences Inc. (NASDAQ: NDRA) is gaining increasing investor attention as the company advances its TAEUS® Liver imaging platform while simultaneously evaluating strategic alternatives aimed at maximizing shareholder value.
Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports
HIVE Digital Technologies is leveraging its significant power infrastructure to pivot from crypto mining into a high-margin sovereign AI data center provider.
